title: The prevalence and clinical significance of autoantibodies to plasminogen activator inhibitor 1 in systemic lupus erythematosus.
abstract: We have recently described the novel autoantigen plasminogen activator inhibitor (PAI-1) in systemic lupus erythematosus (SLE). The aim of this study was to determine the prevalence and clinical significance of anti-PAI-1 autoantibodies in patients with SLE. Autoantibodies to recombinant PAI-1 were measured in retrospective sera of 48 lupus patients by immunoassay in order to assess their clinical significance. This showed that 71% of sera from 48 lupus patients had significantly elevated anti-PAI-1 autoantibodies as compared with normal control subjects (P < 0.0001). There was a weak but significant (P < 0.043) correlation with anti-dsDNA autoantibodies. In longitudinal studies, autoantibodies against PAI-1 correlated with clinical parameters measured by the BILAG disease activity index including global clinical score. Our study demonstrates the high frequency of novel autoantibodies to PAI-1 in patients with lupus. The serial clinical correlations with anti-PAI-1 autoantibodies also support the hypothesis that these autoantibodies may play a pathogenic role in lupus.
authors.affiliation: Molecular Immunology Research Group, School of Applied Sciences, University of Wolverhampton, Wulfuna Street, Wolverhampton WV1 1SB, UK.
authors.forename: R L
authors.initials: RL
authors.lastname: Bates
authors.forename: S J
authors.initials: SJ
authors.lastname: Payne
authors.forename: S L
authors.initials: SL
authors.lastname: Drury
authors.forename: P N
authors.initials: PN
authors.lastname: Nelson
authors.forename: D A
authors.initials: DA
authors.lastname: Isenberg
authors.forename: J J
authors.initials: JJ
authors.lastname: Murphy
authors.forename: G
authors.initials: G
authors.lastname: Frampton
mesh_terms: D000328:Adult; D001323:Autoantibodies / Q000276:immunology*; D001324:Autoantigens / Q000097:blood / Q000276:immunology; D015415:Biomarkers / Q000097:blood; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D008137:Longitudinal Studies; D008180:Lupus Erythematosus, Systemic / Q000097:blood / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood / Q000276:immunology*; D015995:Prevalence; D012189:Retrospective Studies; D012680:Sensitivity and Specificity; D015842:Serine Proteinase Inhibitors / Q000097:blood / Q000276:immunology*; D013223:Statistics as Topic; D016896:Treatment Outcome
chemical_list: D001323:Autoantibodies; D001324:Autoantigens; D015415:Biomarkers; D017395:Plasminogen Activator Inhibitor 1; D015842:Serine Proteinase Inhibitors